MedTrace Logo

Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia

NCT03108690 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-03-29

No results posted yet for this study

Summary

The study investigates whether Therapeutic Drug Monitoring (TDM) and continuous infusion (CI) of beta-lactam antibiotics optimises target concentrations in patients with bacteraemia.

Conditions

  • Bacteremia

Interventions

DRUG

Continuous infusion of beta-lactam antibiotics .

Beta-lactam antibiotic will be administered as continous infusion.

OTHER

Therapeutic drug monitoring of beta-lactam antibiotics.

Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.

Sponsors & Collaborators

  • Sara Thønnings

    lead OTHER

Principal Investigators

  • Sara Thønnings, MD · Hvidovre University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2023-03-09
Completion
2023-03-09

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108690 on ClinicalTrials.gov